Tags
Biomet, Business, Johnson & Johnson, Smith & Nephew, Stryker, Stryker Corporation, UNited States
Is Corin going to be swallowed up?
Hip-replacement specialist Corin was mentioned as another bid target, possibly for 
Smith and Nephew. The cue for the bid chatter was the end of a distribution agreement Corin had with S&N rival Stryker. Smith and Nephew shares were unchanged at 654p, while Corin was up 0.5p to 56p.
Related articles
- Stryker cuts ties with Corin Group amid two new distribution deals (medcitynews.com)
- Smith & Nephew turns attention to emerging economies to counteract tough European market (independent.co.uk)
- Orthopaedics: Market Prospects & Global Competition Share (earlsview.com)
- Is Stryker the Right Stock to Retire With? (fool.com)
Pingback: Corin and Stryker – Stryke Out… « Earl's View
Pingback: Smith & Nephew’s Exclusive OXINIUM Material for Hip Replacement Implants Chosen for Premium Reimbursement in Japan « Earl's View
Pingback: Stryker wants to take on Smith & Nephew in USA « Earl's View
Pingback: History – Smith & Nephew Hip Resurfacing Cups Recalled 2007 « Earl's View
Pingback: Is Oxinium Going to be Safer? Maybe? « Earl's View
Pingback: Hip Arthroscopy Growth Boosts Stryker, ConMed, Smith & Nephew « Earl's View
Pingback: Corin Cormet Post PMA-Approval Study Proposed Protocol « Earl's View
Pingback: Corin Cormet Presentation to FDA Approvals Panel « Earl's View
Pingback: Corin 510K Approval Details « Earl's View
Pingback: Corin 2010 Results – Lackustre Profit Joint (pardon the pun)… « Earl's View
Pingback: FDA Approval for Corin – 510K Approval « Earl's View
Pingback: Economic Sense at Smith & Nephew But will it improve things for Patients? « Earl's View